| 文 峰,向 燕,周艳刚,陈 薇,王少龙.胸腺肽对卵巢癌化疗患者的临床疗效及免疫功能的影响[J].,2018,(16):3148-3152 |
| 胸腺肽对卵巢癌化疗患者的临床疗效及免疫功能的影响 |
| Influence of Thymosin on the Clinical Efficacy and Immune Function of Patients with Ovarian Cancer Undergoing Chemotherapy |
| 投稿时间：2017-10-27 修订日期：2017-11-23 |
| DOI：10.13241/j.cnki.pmb.2018.16.033 |
| 中文关键词: 胸腺肽 卵巢癌 化疗 免疫功能 |
| 英文关键词: Thymic peptide Ovarian cancer Chemotherapy Immune function |
| 基金项目: |
|
| 摘要点击次数: 549 |
| 全文下载次数: 354 |
| 中文摘要: |
| 摘要 目的：探讨胸腺肽对卵巢癌化疗患者临床疗效及免疫功能的影响。方法：选取2015年1月到2017年1月期间我院收治的184例卵巢癌患者作为研究对象，随机分为观察组和对照组，每组各92例。对照组接受紫杉醇联合顺铂/卡铂的化疗方案，观察组在对照组化疗方案的基础上，加用胸腺肽注射液静脉滴注。比较两组患者的临床疗效，治疗前后CD3、CD4、CD8、CD4/CD8、NK细胞以及IgA、IgG、IgM的变化及不良反应的发生情况。结果：治疗后，观察组的总有效率为45.65 %，疾病控制率为86.96 %，均显著高于对照组(均P＜0.05)；观察组的CD3为(67.38±6.31) %，CD4为(44.29±6.02) %，CD4/CD8为(1.67±0.18)，NK细胞为(15.71±4.39) %，IgA为(2.43±0.21) g/L，IgG为(10.04±1.02) g/L，IgM为(1.17±0.93) g/L，均显著高于治疗前和对照组(均P＜0.05)；观察组的不良反应发生率为20.65 %，显著低于对照组(P＜0.05)。结论：胸腺肽可显著提高卵巢癌化疗患者的临床疗效，改善患者机体的免疫功能，减轻化疗所致的不良反应。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the influence of thymosin on the clinical efficacy and immune function of patients with ovarian cancer undergoing chemotherapy. Methods: 184 cases of patients with ovarian cancer were selected from January 2015 to January 2017 and randomly divided into the observation group and the control group, with 92 cases in each group. The control group was given paclitaxel and cisplatin/carboplatin chemotherapy, and the observation group was given thymosin on the basis of control group. The clinical efficacy, changes of CD3, CD4, CD8, CD4/CD8, NK cells, IgA, IgG and IgM before and after treatment as well as the incidence of adverse reactions were compared between two groups. Results: The total effective rate of observation group was 45.65 %, the disease control rate was 86.96 %, which were significantly higher than those of the control group (P<0.05). After treatment, the level of CD3 of observation group was (67.38 ± 6.31) %, CD4 was (44.29 ± 6.02) %, CD4/CD8 was (1.67 ± 0.18), NK cells was (15.71 ± 4.39) %, IgA was (2.43 ± 0.21) g/L, IgG was (10.04 ± 1.02) g/L, IgM was (1.17 ± 0.93) g/L, which were significantly higher than those before treatment and those of the control group (P<0.05). The incidence of adverse reactions in the observation group was 20.65 %, which was significantly lower than that of the control group (P<0.05). Conclusion: Thymosin can significantly improve the clinical efficacy of patients with ovarian cancer undergoing chemotherapy, improve the immune function of patients, and reduce the adverse reactions of chemotherapy. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
